Zentalis Pharmaceuticals Statistics
Total Valuation
ZNTL has a market cap or net worth of $287.27 million. The enterprise value is $80.95 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ZNTL has 70.93 million shares outstanding. The number of shares has increased by 1.11% in one year.
| Current Share Class | 70.93M |
| Shares Outstanding | 70.93M |
| Shares Change (YoY) | +1.11% |
| Shares Change (QoQ) | -0.66% |
| Owned by Insiders (%) | 1.59% |
| Owned by Institutions (%) | 53.28% |
| Float | 48.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.93, with a Debt / Equity ratio of 0.18.
| Current Ratio | 6.93 |
| Quick Ratio | 6.73 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.53% and return on invested capital (ROIC) is -27.70%.
| Return on Equity (ROE) | -49.53% |
| Return on Assets (ROA) | -24.48% |
| Return on Invested Capital (ROIC) | -27.70% |
| Return on Capital Employed (ROCE) | -55.81% |
| Weighted Average Cost of Capital (WACC) | 11.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 106 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ZNTL has paid $442,000 in taxes.
| Income Tax | 442,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +183.22% in the last 52 weeks. The beta is 1.66, so ZNTL's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | +183.22% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 2.07 |
| Relative Strength Index (RSI) | 53.25 |
| Average Volume (20 Days) | 4,543,293 |
Short Selling Information
The latest short interest is 5.20 million, so 7.34% of the outstanding shares have been sold short.
| Short Interest | 5.20M |
| Short Previous Month | 4.26M |
| Short % of Shares Out | 7.34% |
| Short % of Float | 10.69% |
| Short Ratio (days to cover) | 1.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -140.88M |
| Pretax Income | -136.62M |
| Net Income | -137.06M |
| EBITDA | -140.14M |
| EBIT | -140.88M |
| Earnings Per Share (EPS) | -$1.91 |
Full Income Statement Balance Sheet
The company has $245.89 million in cash and $39.58 million in debt, giving a net cash position of $206.32 million or $2.91 per share.
| Cash & Cash Equivalents | 245.89M |
| Total Debt | 39.58M |
| Net Cash | 206.32M |
| Net Cash Per Share | $2.91 |
| Equity (Book Value) | 216.20M |
| Book Value Per Share | 3.13 |
| Working Capital | 216.63M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -125.25M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 739,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -125.25M |
| FCF Per Share | -$1.77 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |